Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Verastem ( (VSTM) ).
On June 2, 2025, Verastem Oncology announced positive results from a Phase 1 study of their drug VS-7375, conducted in China by partner GenFleet Therapeutics, targeting advanced KRAS G12D mutant solid tumors. The study showed promising efficacy with an overall response rate of 52% in pancreatic ductal adenocarcinoma patients and 42% in non-small cell lung cancer patients, with no dose-limiting toxicities observed. These results were presented at the 2025 ASCO Annual Meeting, and Verastem plans to initiate a Phase 1/2a study in the U.S., potentially expanding globally, to further evaluate the drug’s safety and efficacy.
The most recent analyst rating on (VSTM) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Verastem stock, see the VSTM Stock Forecast page.
Spark’s Take on VSTM Stock
According to Spark, TipRanks’ AI Analyst, VSTM is a Neutral.
Verastem’s overall stock score is primarily impacted by its weak financial performance, characterized by ongoing losses and negative equity. However, positive technical indicators and recent corporate events, such as the $75M private placement, provide some optimism for future growth. Valuation remains constrained by negative earnings, but strategic initiatives and product development efforts could drive improvements. The stock represents a speculative opportunity, with potential upside if financial health and operational efficiencies improve.
To see Spark’s full report on VSTM stock, click here.
More about Verastem
Verastem Oncology is a biopharmaceutical company focused on developing and commercializing new medicines for RAS/MAPK pathway-driven cancers. The company’s pipeline includes novel small molecule drugs targeting critical cancer signaling pathways, such as RAF/MEK, FAK, and KRAS G12D inhibition.
Average Trading Volume: 1,421,906
Technical Sentiment Signal: Buy
Current Market Cap: $413.2M
For a thorough assessment of VSTM stock, go to TipRanks’ Stock Analysis page.